Founded in 2020, Gradient Denervation Technologies is a medical device start-up developing a groundbreaking minimally invasive catheter-based therapy using ultrasound thermal ablation to treat pulmonary arterial hypertension —a devastating disease for which no therapeutic options currently exist.

Based on a patented innovation developed by physicians at Stanford University, Gradient’s technology is a clinical-stage company driven by the ambition to deliver a durable therapeutic solution and improving patients’ longevity and quality of life.

The company brings together a young, passionate international team spread across France (headquartered in Suresnes, Paris area), the United States, and Ireland united by a shared mission: turning research into tangible clinical impact.

Recipient of several prestigious awards, including the i-Lab Innovation Competition and a third-place finish at the EIT Health Catapult, and the Innov’up Leader Award, Gradient is distinguished by its culture of scientific excellence, its entrepreneurial mindset, and a stimulating environment, in which ideas quickly turn into concrete projects.

In May 2025, the company received both FDA Breakthrough Device designation and acceptance into the Total Product Life Cycle Advisory Program (TAP) for its pulmonary denervation system, further validating the unique and promising potential of its technology on the international stage.